Vee Perearstikeskus OÜ
- Address
- lock Available on a paid plan
Virus Diseases and Respiratory Tract Diseases
At Vee Perearstikeskus OÜ in Paide, Estonia, clinical research in these areas focuses on common respiratory and viral illnesses, especially influenza and respiratory syncytial virus infections. The trials are designed to assess the safety, immune response, and overall effectiveness of new vaccine candidates and related preventive approaches.
- Studying a new influenza vaccine to see how well it protects against seasonal flu
- Evaluating immune responses to RSV vaccination in older adults
- Assessing the safety and tolerability of preventive vaccines for viral respiratory disease
This work supports better protection against infections that can cause significant illness in both older adults and vulnerable populations.
Bacterial Infections and Mycoses
Research in bacterial infections at this site centers on pneumococcal immunization and the prevention of disease caused by Streptococcus pneumoniae. The studies aim to compare vaccine responses, confirm protection across age groups, and further evaluate safety in infants, toddlers, children, and adolescents.
- Testing a pneumococcal conjugate vaccine for immune protection in young children
- Comparing vaccine performance across different age groups to support broader use
- Monitoring safety and immune response after catch-up vaccination
These trials help advance vaccination strategies against a major bacterial cause of respiratory and invasive disease.
Virus Diseases and Bacterial Infections and Mycoses
The site also contributes to vaccine research for childhood and adolescent prevention, including varicella and pneumococcal immunization. These studies are focused on confirming that vaccine lots are consistent, safe, and capable of producing a strong immune response.
- Evaluating a chickenpox vaccine for immune response and safety in healthy children
- Checking consistency between vaccine manufacturing lots
- Comparing investigational vaccines with established options to support prevention
Overall, the research supports reliable immunization programs aimed at reducing preventable infectious diseases across pediatric populations.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 3 therapeutic areas and 15 of 45 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 45 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 1 by active trials.
- 1GlaxoSmithKline Biologicals1active
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1GlaxoSmithKline Biologicals2trials
lock +1 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 44 other sites in Estonia
Therapeutic Area Benchmark — Estonia
Select a therapeutic area to compare against other sites in Estonia.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Estonia
Market Share
Country: Estonia
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Vee Perearstikeskus OÜ
lock Showing 1 of 6 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Evaluation of Immunogenicity and Safety of RSVPreF3 OA Vaccine in Adults Aged 60+ Following Revaccination Schedules in a Phase 3b Extension Study | GlaxoSmithKline Biologicals | Phase III | Not Recruiting | Aug 2024 | — |
IMP list
lock Showing 1 of 45 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Influenza Virus B/Austria/1359417/2021-Like Strain (B/Austria/1359417/2021, Bvr-26) | 2 | Unknown | 2023-11-03 | 2024-10-11 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.